Literature DB >> 32984909

Impact of oral antibiotic prophylaxis on surgical site infection after rectal surgery: results of randomized trial.

Evgeny Rybakov1, Marat Nagudov2, Marina Sukhina2, Yuri Shelygin2,3.   

Abstract

AIM: To evaluate the impact of oral antibiotic prophylaxis on surgical site infection (SSI) rate after rectal surgery.
METHODS: It was a single-center 1:1 randomized controlled open parallel trial (registration number NCT03436719). The patients undergoing rectal resection for benign and malignant tumors were assigned randomly to two groups: the oral plus intravenous (IV) antibiotic prophylaxis (AP) and the IV antibiotic prophylaxis only. The primary endpoint was the overall rate of SSI.
RESULTS: Between November 2017 and December 2018, 116 (male-55, the mean age-64 years) patients were enrolled into the trial. Of them, 57 had oral erythromycin 500 mg + metronidazole 500 mg a day before surgery and 1,000 mg of cephalosporin IV 30-90 min before operation. In the other group, 59 patients had the same IV antibiotics only. The incidence of SSIs was 22% (13/59) and 3.5% (2/57) correspondingly (р = 0.002). The statistically significant difference was detected for superficial SSI 0 (0%) vs. 5 (8.5%) (p = 0.03) and organ/space SSI 2 (3.5%) vs. 9 (15.3%) (p = 0.03), respectively. A multivariate analysis of risk factors of SSI identified two independent ones: bacterial contamination of the pelvic cavity ≥ 105 CFU at the end of surgery OR 17.9, 95% CI 2.1-150.0 (p = 0.008) and oral antimicrobial prophylaxis OR 0.2, 95% CI 0.03-0.8 (p = 0.02).
CONCLUSION: Oral-parenteral AP significantly reduced the risk of SSI following elective rectal surgery. Bacterial contamination of the pelvic cavity ≥ 105 CFU at the end of surgery and oral antimicrobial prophylaxis were independent risk factors of SSI.

Entities:  

Keywords:  Colorectal surgery; Mechanical bowel preparation; Oral antibiotics; Surgical site infection

Mesh:

Substances:

Year:  2020        PMID: 32984909     DOI: 10.1007/s00384-020-03746-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  12 in total

1.  Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee.

Authors:  A J Mangram; T C Horan; M L Pearson; L C Silver; W R Jarvis
Journal:  Infect Control Hosp Epidemiol       Date:  1999-04       Impact factor: 3.254

2.  Oral and Parenteral Versus Parenteral Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery (JMTO PREV 07-01): A Phase 3, Multicenter, Open-label, Randomized Trial.

Authors:  Hiroaki Hata; Takashi Yamaguchi; Suguru Hasegawa; Akinari Nomura; Koya Hida; Ryuta Nishitai; Satoshi Yamanokuchi; Takeharu Yamanaka; Yoshiharu Sakai
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

3.  Effect of preoperative neomycin-erythromycin intestinal preparation on the incidence of infectious complications following colon surgery.

Authors:  R L Nichols; P Broido; R E Condon; S L Gorbach; L M Nyhus
Journal:  Ann Surg       Date:  1973-10       Impact factor: 12.969

4.  Surgical site infections in colon surgery: the patient, the procedure, the hospital, and the surgeon.

Authors:  Martin Hübner; Michele Diana; Giorgio Zanetti; Marie-Christine Eisenring; Nicolas Demartines; Nicolas Troillet
Journal:  Arch Surg       Date:  2011-07-18

5.  A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls.

Authors:  M L Baum; D S Anish; T C Chalmers; H S Sacks; H Smith; R M Fagerstrom
Journal:  N Engl J Med       Date:  1981-10-01       Impact factor: 91.245

6.  Randomized clinical trial of oral and intravenous versus intravenous antibiotic prophylaxis for laparoscopic colorectal resection.

Authors:  A Ikeda; T Konishi; M Ueno; Y Fukunaga; S Nagayama; Y Fujimoto; T Akiyoshi; T Yamaguchi
Journal:  Br J Surg       Date:  2016-08-23       Impact factor: 6.939

7.  Factors involved in antibiotic selection in elective colon and rectal surgery.

Authors:  G F Coppa; K Eng
Journal:  Surgery       Date:  1988-11       Impact factor: 3.982

Review 8.  Combination of oral non-absorbable and intravenous antibiotics versus intravenous antibiotics alone in the prevention of surgical site infections after colorectal surgery: a meta-analysis of randomized controlled trials.

Authors:  C F Bellows; K T Mills; T N Kelly; G Gagliardi
Journal:  Tech Coloproctol       Date:  2011-07-23       Impact factor: 3.781

9.  Randomized multicentre trial of oral bowel preparation and antimicrobials for elective colorectal operations.

Authors:  D M Matheson; Y Arabi; D Baxter-Smith; J Alexander-Williams; M R Keighley
Journal:  Br J Surg       Date:  1978-09       Impact factor: 6.939

10.  Risk factors and outcomes of organ-space surgical site infections after elective colon and rectal surgery.

Authors:  Aina Gomila; Jordi Carratalà; Daniel Camprubí; Evelyn Shaw; Josep Mª Badia; Antoni Cruz; Francesc Aguilar; Carmen Nicolás; Anna Marrón; Laura Mora; Rafel Perez; Lydia Martin; Rosa Vázquez; Ana Felisa Lopez; Enric Limón; Francesc Gudiol; Miquel Pujol
Journal:  Antimicrob Resist Infect Control       Date:  2017-04-21       Impact factor: 4.887

View more
  3 in total

1.  Oral antibiotics and mechanical bowel preps: do they have to come together?

Authors:  Richard Nelson
Journal:  Int J Colorectal Dis       Date:  2021-02-18       Impact factor: 2.571

2.  Mechanical bowel preparation with or without oral antibiotics for rectal resection for cancer (REPCA trial): a study protocol for a multicenter randomized controlled trial.

Authors:  Aleksandra Olkina; Aleksei Karachun; Sergey Bagnenko; Alexey Belyaev; Aleksei Petrov
Journal:  Tech Coloproctol       Date:  2022-09-24       Impact factor: 3.699

3.  Mechanical bowel preparation and oral antibiotics versus mechanical bowel preparation only prior rectal surgery (MOBILE2): a multicentre, double-blinded, randomised controlled trial-study protocol.

Authors:  Laura Koskenvuo; Pipsa Lunkka; Pirita Varpe; Marja Hyöty; Reetta Satokari; Carola Haapamäki; Anna Lepistö; Ville Sallinen
Journal:  BMJ Open       Date:  2021-07-09       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.